Qualigen Therapeutics Inc. - notizie pubblicate 74 - letture 1.075
QUALIGEN THERAPEUTICS INC.
Change in Certifying Accountants Form 8 K
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer qualigen therapeutic ...
QUALIGEN THERAPEUTICS INC.
Material Agreement Form 8 K
Item 1.01. entry into a material definitive agreement. as previously reported, qualigen therapeutics, inc. (the "company") and an institutional investor entered into a se ...
QUALIGEN THERAPEUTICS INC.
Material Agreement Form 8 K
Item 1.01. entry into a material definitive agreement. qualigen therapeutics, inc. (the "company") and an institutional investor entered into a securities purchase agreem ...
QUALIGEN THERAPEUTICS INC.
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Chaska, minn., july 01, 2024 (globe newswire) -- lifecore biomedical, inc. (nasdaq: lfcr) ("lifecore" or the "company"), a fully integrated contract development ...
QUALIGEN THERAPEUTICS INC.
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination - Form 8-K
Qualigen therapeutics, inc. received nasdaq notice of a delisting determination carlsbad, calif., may 30, 2024 (globe newswire) - qualigen therapeutics, inc. ("qualigen" ...
QUALIGEN THERAPEUTICS INC.
Late Filing Notice - Form NT 10-Q
United states securities and exchange commission washington, d.c. 20549 omb approval omb number: 3235-0058 expires: april 30, 2025 estimated average burden hours per response 2.50 ...
QUALIGEN THERAPEUTICS INC.
Amendment to Initial Registration Statement - Form S-1/A
As filed with the securities and exchange commission on may 3, 2024. registration no. 333-272623 united states securities and exchange commission washington, d.c. 20549 amendment n ...
QUALIGEN THERAPEUTICS INC.
Notice of Effectiveness - Form EFFECT
Notice of effectiveness united states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: may 2, 2024 accession number: 0001493152 ...
QUALIGEN THERAPEUTICS INC.
Post-Effective Amendment to Registration Statement - Form POS AM
As filed with the securities and exchange commission on april 30, 2024 registration no. 333-269088 united states securities and exchange commission washington, d.c. 20549 post-effe ...
QUALIGEN THERAPEUTICS INC.
Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ - Form 8-K
Marizyme enters into co-development agreement with qualigen therapeutics for the commercialization of fda-cleared duragraft™ jupiter, fl, april 16, 2024 (globe newswire) - via ne ...
QUALIGEN THERAPEUTICS INC.
Annual Report for Fiscal Year Ending December 31, 2023 (Form 10-K)
United states securities and exchange commission washington, d.c. 20549 form 10-k ☒ annual report pursuant to section 13 or 15(d) of the securities exchange act of 1934 for the f ...
QUALIGEN THERAPEUTICS INC.
Late Filing Notice - Form NT 10-K
United states securities and exchange commission washington, d.c. 20549 omb approval omb number: 3235-0058 expires: april 30, 2025 estimated average burden hours per response 2.50 ...
QUALIGEN THERAPEUTICS INC.
Termination of Material Agreement - Form 8-K
Item 1.02. termination of a material definitive agreement. on march 25, 2024, as of march 16, 2024, we entered into a termination agreement with pan-ras holdings, inc., a new york ...
QUALIGEN THERAPEUTICS INC.
Material Agreement - Form 8-K
Item 1.01. entry into a material definitive agreement. on february 26, 2024, qualigen therapeutics, inc. (the "company") entered into a securities purchase agreement (&qu ...
QUALIGEN THERAPEUTICS INC.
Material Agreement - Form 8-K
Item 1.01. entry into a material definitive agreement. on february 15, 2024, we entered into a license and sublicense agreement with pan-ras holdings, inc., a new york corporation ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti